Healthcare

SB 1031, the "Restore Trust in Public Health Messaging Act," requires Tennessee's health departments and state agencies to align all public communications about FDA-approved drugs and medical products with the FDA's official labels. It directly affects the Tennessee Department of Health, local health departments, and state executive branch employees who share information about medications or health products. The bill prohibits promoting claims that conflict with FDA labels, mandates internal reviews by July 2025, and requires annual compliance reports to the legislature. Violations trigger investigations by the comptroller, with potential penalties for noncompliance. This law aims to ensure state health messaging is scientifically accurate and consistent with federal standards.

SB 318, the "Tennessee Genomic Security and End Organ Harvesting Act," prohibits Tennessee health insurers from covering organ transplants sourced from the People's Republic of China or performed there, effective January 1, 2026. It also bans medical and research facilities from using genetic sequencing equipment or software produced by or linked to "foreign adversaries" (defined as nations on U.S. sanctions lists), requiring replacement within 180 days. The bill restricts storage of genetic sequencing data to U.S. geographic locations and prohibits remote access from outside the U.S. without state health commissioner approval. These provisions directly affect health insurers, hospitals, and research facilities operating in Tennessee.

SB 282, the "Individualized Investigational Treatment Act," creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized medical treatments (like gene therapies or vaccines tailored to their genetic profile) when standard FDA-approved options have been exhausted. It directly affects eligible patients (who must meet specific criteria including physician attestation and written informed consent) and eligible facilities (those complying with federal human subjects protections). Key provisions require detailed written consent covering all treatment options, risks, and financial liability, while clarifying that insurers, health plans, and providers are **not obligated** to cover these treatments or related costs (TCA §§ 63-6-1304(a)-(d)). The law takes effect July 1, 2025, and explicitly states that heirs cannot be held liable for unpaid treatment debts if a patient dies during treatment (TCA § 63-6-1305).